Biotech Values

[DewDiligence]

[Barron’s]: “[PFE has] some drugs in its pipeline that could prove to be important, including treatments for rheumatoid arthritis and lung cancer.”

[turtlepower]: Obviously, Barron’s is not up to date

Barron’s is indeed up to date. You may have been confusing Tanezumab , PFE’s NGF mAb for osteoarthritis (which was put on clinical hold by the FDA in June: #msg-51634760) with CP-690,550, PFE’s JAK3 inhibitor for RA, which is very much alive.